Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2024

Using the Australian Cardio-Oncology Registry (ACOR) to study Long-term Cancer Therapy Related Cardiac Dysfunction (CTRCD) in Adult Oncology Patients – The Chris O’Brien Lifehouse (COBLH) experience (#564)

Jocelyn Finney 1 , Sanjeev Kumar 1 , Lisa Horvath 1 , David Celermajer 2 , Rachel Conyers 3
  1. Medical Oncology , Chris O’Brien Lifehouse , Sydney, NSW, Australia
  2. Cardiology, University of Sydney, Sydney, NSW, Australia
  3. Paediatric Oncology, The Royal Children’s Hospital, Melbourne , Victoria , Australia

Aims:

CTRCD is a significant side effect of several chemotherapies, targeted agents, and immunotherapies integral to treatment. Currenting in Australia, the ACOR is the only multi-centre, longitudinal study examining CTRCD. COBLH aims to use the ACOR to explore the epidemiology, clinical presentation, and management of CTRCD amongst adult oncology patients receiving cardiotoxic therapies. In addition, a biobanking sub-study will seek to evaluate if genetic variants in cardiomyopathy-related genes predispose carriers to developing anthracycline cardiotoxicity (ACT). This will aim to contribute to the introduction of an ACT susceptibility genetic screening test which will ensure the inclusion of patient risk stratification prior to anthracycline exposure in routine cancer treatment.

 

Methods:

The ACOR is a prospective observational non-interventional study involving 14 sites across Australia. COBLH patient criteria includes curative intent high risk adult patients treated with cardiotoxic therapies within the last 5 years. Information is obtained from medical records and de-identified upon entry into the ACOR. Patient demographics, medical history, cancer diagnosis, treatment, cardiac evaluations, and the management of demonstrated CTRCD are recorded. These instruments are collected at baseline prior to treatment, and at six-month intervals thereafter. Descriptive statistics will be used for variables for quantitative analysis and Kaplan Meier analyses will be used for survival curves and freedom from cardiac failure and arrhythmia since enrolment. Patients who develop ACT will be asked to participate in the biobanking sub-study, which will involve a one-off 10mL blood draw that will be processed for whole genome exome sequencing.

 

Results:

COBLH have collected data from 359 patients; 48 sarcoma patients and 311 breast cancer patients. 33 of these patients have developed ACT and will be consented to the biobanking sub-study.

 

Conclusions:

The ACOR is examining CTRCD in adult oncology patients and the biobanking study is seeking to prove a causal association between genetic predisposition and ACT.